Molecular genetic characterization reveals new subsets of mantle cell lymphoma

References

• Argatoff L H, Connors J M, Klasa R J, Horsman D E, Gascoyne R D. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997; 89: 2067–2078
   PubMed Web of Science ®Google Scholar
• E S Jaffe, Harris, N L, Stein, H, Vardiman, J W. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Haematopoetic and Lymphoid Tissues. Lyon, IARC Press. 2001
   Google Scholar
• Howard O M, Gribben J G, Neuberg D S, Grossbard M, Poor C, Janicek M J, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288–1294
   PubMed Web of Science ®Google Scholar
• Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105: 2677–2684
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984–1992
   PubMed Web of Science ®Google Scholar
• Witzig T E. Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 2005; 23: 6409–6414
   PubMed Web of Science ®Google Scholar
• Leonard J P, Furman R R, Coleman M. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma. Int J Cancer 2006; 119: 971–979
   PubMed Web of Science ®Google Scholar
• Greiner T C, Moynihan M J, Chan W C, Lytle D M, Pedersen A, Anderson J R, et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 1996; 87: 4302–4310
   PubMed Web of Science ®Google Scholar
• Hernandez L, Fest T, Cazorla M, Teruya-Feldstein J, Bosch F, Peinado M A, et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 1996; 87: 3351–3359
   PubMed Web of Science ®Google Scholar
• Bea S, Ribas M, Hernandez J M, Bosch F, Pinyol M, Hernandez L, et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 1999; 93: 4365–4374
   PubMed Web of Science ®Google Scholar
• Swerdlow S H, Williams M E. From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades. Hum Pathol 2002; 33: 7–20
   PubMed Web of Science ®Google Scholar
• Gladden A B, Diehl J A. Location, location, location: the role of cyclin D1 nuclear localization in cancer. J Cell Biochem 2005; 96: 906–913
   PubMed Web of Science ®Google Scholar
• Gladden A B, Woolery R, Aggarwal P, Wasik M A, Diehl J A. Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene 2006; 25: 998–1007
   PubMed Web of Science ®Google Scholar
• Fu K, Weisenburger D D, Greiner T C, Dave S, Wright G, Rosenwald A, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005; 106: 4315–4321
   PubMed Web of Science ®Google Scholar
• Salaverria I, Zettl A, Bea S, Moreno V, Valls J, Hartmann E, et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 2007; 25: 1216–1222
   PubMed Web of Science ®Google Scholar
• Raty R, Franssila K, Joensuu H, Teerenhovi L, Elonen E. Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol 2002; 69: 11–20
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Wiestner A, Chan W C, Connors J M, Campo E, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3: 185–197
   PubMed Web of Science ®Google Scholar
• Flordal Thelander E, Ichimura K, Collins V P, Walsh S H, Barbany G, Hagberg A, et al. Detailed assessment of copy number alterations revealing homozygous deletions in lp and 13q in mantle cell lymphoma. Leuk Res 2007; 31: 1219–1230
   PubMed Web of Science ®Google Scholar
• Fugmann S D, Lee A I, Shockett P E, Villey I J, Schatz D G. The RAG proteins and V(D)J recombination: complexes, ends, and transposition. Annu Rev Immunol 2000; 18: 495–527
   PubMed Web of Science ®Google Scholar
• Lewis S M. The mechanism of V(D)J joining: lessons from molecular, immunological, and comparative analyses. Adv Immunol 1994; 56: 27–150
   PubMed Web of Science ®Google Scholar
• Papavasiliou F N, Schatz D G. Somatic hypermutation of immunoglobulin genes: merging mechanisms for genetic diversity. Cell 2002; 109: S35–S44
   PubMed Web of Science ®Google Scholar
• Rada C, Williams G T, Nilsen H, Barnes D E, Lindahl T, Neuberger M S. Immunoglobulin isotype switching is inhibited and somatic hypermutation perturbed in UNG-deficient mice. Curr Biol 2002; 12: 1748–1755
   PubMed Web of Science ®Google Scholar
• Kuppers R, Klein U, Hansmann M L, Rajewsky K. Cellular origin of human B-cell lymphomas. N Engl J Med 1999; 341: 1520–1529
   PubMed Web of Science ®Google Scholar
• Bird J, Galili N, Link M, Stites D, Sklar J. Continuing rearrangement but absence of somatic hypermutation in immunoglobulin genes of human B cell precursor leukemia. J Exp Med 1988; 168: 229–245
   PubMed Web of Science ®Google Scholar
• Bahler D W, Campbell M J, Hart S, Miller R A, Levy S, Levy R. Ig VH gene expression among human follicular lymphomas. Blood 1991; 78: 1561–1568
   PubMed Web of Science ®Google Scholar
• Kuppers R, Rajewsky K, Hansmann M L. Diffuse large cell lymphomas are derived from mature B cells carrying V region genes with a high load of somatic mutation and evidence of selection for antibody expression. Eur J Immunol 1997; 27: 1398–1405
   PubMed Web of Science ®Google Scholar
• Lossos I S, Alizadeh A A, Eisen M B, Chan W C, Brown P O, Botstein D, et al. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. Proc Natl Acad Sci USA 2000; 97: 10209–10213
   PubMed Web of Science ®Google Scholar
• Rettig M B, Vescio R A, Cao J, Wu C H, Lee J C, Han E, et al. VH gene usage is multiple myeloma: complete absence of the VH4.21 (VH4-34) gene. Blood 1996; 87: 2846–2852
   PubMed Web of Science ®Google Scholar
• Damle R N, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S L, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847
   PubMed Web of Science ®Google Scholar
• Hamblin T J, Davis Z, Gardiner A, Oscier D G, Stevenson F K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854
   PubMed Web of Science ®Google Scholar
• Chiorazzi N, Rai K R, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804–815
   PubMed Web of Science ®Google Scholar
• Walsh S H, Rosenquist R. Immunoglobulin gene analysis of mature B-cell malignancies: reconsideration of cellular origin and potential antigen involvement in pathogenesis. Med Oncol 2005; 22: 327–341
   PubMed Web of Science ®Google Scholar
• Camacho F I, Algara P, Rodriguez A, Ruiz-Ballesteros E, Mollejo M, Martinez N, et al. Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood 2003; 101: 4042–4046
   PubMed Web of Science ®Google Scholar
• Kienle D, Krober A, Katzenberger T, Ott G, Leupolt E, Barth T F, et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood 2003; 102: 3003–3009
   PubMed Web of Science ®Google Scholar
• Walsh S H, Thorsélius M, Johnson A, Söderberg O, Jerkeman M, Björck E, et al. Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. Blood 2003; 101: 4047–4054
   PubMed Web of Science ®Google Scholar
• Lai R, Lefresne S V, Franko B, Hui D, Mirza I, Mansoor A, et al. Immunoglobulin VH somatic hypermutation in mantle cell lymphoma: mutated genotype correlates with better clinical outcome. Mod Pathol 2006; 19: 1498–1505
   PubMed Web of Science ®Google Scholar
• Orchard J, Garand R, Davis Z, Babbage G, Sahota S, Matutes E, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003; 101: 4975–4981
   PubMed Web of Science ®Google Scholar
• Inagaki H, Nakamura T, Li C, Sugiyama T, Asaka M, Kodaira J, et al. Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter pylori eradication and detection of API2-MALT1 fusion. Am J Surg Pathol 2004; 28: 1560–1567
   PubMed Web of Science ®Google Scholar
• Du M Q. MALT Lymphoma: recent advances in aetiology and molecular genetics. J Clin Exp Hematop 2007; 47: 31–42
   PubMedGoogle Scholar
• Viswanatha D S, Dogan A. Hepatitis C virus and lymphoma. J Clin Pathol 2007; 60: 1378–1383
   PubMed Web of Science ®Google Scholar
• Johnson T A, Rassenti L Z, Kipps T J. Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol 1997; 158: 235–246
   PubMed Web of Science ®Google Scholar
• Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, Allen S L, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998; 102: 1515–1525
   PubMed Web of Science ®Google Scholar
• Rosenquist R, Lindström A, Holmberg D, Lindh J, Roos G. V(H) gene family utilization in different B-cell lymphoma subgroups. Eur J Haematol 1999; 62: 123–128
   PubMed Web of Science ®Google Scholar
• Tobin G, Thunberg U, Johnson A, Eriksson I, Söderberg O, Karlsson K, et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 2003; 101: 4952–4957
   PubMed Web of Science ®Google Scholar
• Thorsélius M, Walsh S, Eriksson I, Thunberg U, Johnson A, Backlin C, et al. Somatic hypermutation and V(H) gene usage in mantle cell lymphoma. Eur J Haematol 2002; 68: 217–224
   PubMed Web of Science ®Google Scholar
• Fang Q, Kannapell C C, Gaskin F, Solomon A, Koopman W J, Fu S M. Human rheumatoid factors with restrictive specificity for rabbit immunoglobulin G: auto- and multi-reactivity, diverse VH gene segment usage and preferential usage of V lambda IIIb. J Exp Med 1994; 179: 1445–156
   PubMed Web of Science ®Google Scholar
• Elagib K E, Tengner P, Levi M, Jonsson R, Thompson K M, Natvig J B, et al. Immunoglobulin variable genes and epitope recognition of human monoclonal anti-Ro 52-kd in primary Sjogren's syndrome. Arthritis Rheum 1999; 42: 2471–2481
   PubMed Web of Science ®Google Scholar
• Cappione A J, Pugh-Bernard A E, Anolik J H, Sanz I. Lupus IgG VH4.34 antibodies bind to a 220-kDa glycoform of CD45/B220 on the surface of human B lymphocytes. J Immunol 2004; 172: 4298–4307
   PubMed Web of Science ®Google Scholar
• Tobin G, Thunberg U, Johnson A, Thörn I, Söderberg O, Hultdin M, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002; 99: 2262–2264
   PubMed Web of Science ®Google Scholar
• Stamatopoulos K, Belessi C, Moreno C, Boudjograh M, Guida G, Smilevska T, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007; 109: 259–270
   PubMed Web of Science ®Google Scholar
• Hillson J L, Karr N S, Oppliger I R, Mannik M, Sasso E H. The structural basis of germline-encoded VH3 immunoglobulin binding to staphylococcal protein A. J Exp Med 1993; 178: 331–336
   PubMed Web of Science ®Google Scholar
• Bertoni F, Zucca E, Cotter F E. Molecular basis of mantle cell lymphoma. Br J Haematol 2004; 124: 130–140
   PubMed Web of Science ®Google Scholar
• Bodrug S E, Warner B J, Bath M L, Lindeman G J, Harris A W, Adams J M. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. Embo J 1994; 13: 2124–2130
   PubMed Web of Science ®Google Scholar
• Lovec H, Grzeschiczek A, Kowalski M B, Moroy T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. Embo J 1994; 13: 3487–3495
   PubMed Web of Science ®Google Scholar
• Kohlhammer H, Schwaenen C, Wessendorf S, Holzmann K, Kestler H A, Kienle D, et al. Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. Blood 2004; 104: 795–801
   PubMed Web of Science ®Google Scholar
• Rubio-Moscardo F, Climent J, Siebert R, Piris M A, Martin-Subero J I, Nielander I, et al. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 2005; 105: 4445–4454
   PubMed Web of Science ®Google Scholar
• Schraders M, Pfundt R, Straatman H M, Janssen I M, van Kessel A G, Schoenmakers E F, et al. Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization. Blood 2005; 105: 1686–1693
   PubMed Web of Science ®Google Scholar
• Tagawa H, Karnan S, Suzuki R, Matsuo K, Zhang X, Ota A, et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 2005; 24: 1348–1358
   PubMed Web of Science ®Google Scholar
• Rinaldi A, Kwee I, Taborelli M, Largo C, Uccella S, Martin V, et al. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol 2006; 132: 303–316
   PubMed Web of Science ®Google Scholar
• Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic Aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916
   PubMed Web of Science ®Google Scholar
• Aoun P, Blair H E, Smith L M, Dave B J, Lynch J, Weisenburger D D, et al. Fluorescence in situ hybridization detection of cytogenetic abnormalities in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma 2004; 45: 1595–1603
   PubMed Web of Science ®Google Scholar
• Parry-Jones N, Matutes E, Morilla R, Brito-Babapulle V, Wotherspoon A, Swansbury G J, et al. Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISH. Br J Haematol 2007; 137: 117–124
   PubMed Web of Science ®Google Scholar
• Stilgenbauer S, Schaffner C, Winkler D, Ott G, Leupolt E, Bentz M, et al. The ATM gene in the pathogenesis of mantle-cell lymphoma. Ann Oncol 2000; 11: 127–130
   PubMed Web of Science ®Google Scholar
• Flordal Thelander E, Walsh S H, Thorsélius M, Laurell A, Landgren O, Larsson C, et al. Mantle cell lymphomas with clonal immunoglobulin V(H)3-21 gene rearrangements exhibit fewer genomic imbalances than mantle cell lymphomas utilizing other immunoglobulin V(H) genes. Mod Pathol 2005; 18: 331–339
   PubMed Web of Science ®Google Scholar
• Mestre-Escorihuela C, Rubio-Moscardo F, Richter J A, Siebert R, Climent J, Fresquet V, et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 2006; 109: 271–280
   PubMed Web of Science ®Google Scholar